|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - Nussbaum Ran
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2019-06-27 Purchase |
2019-07-01 11:50 am |
ARQULE INC | ARQL | Nussbaum Ran Director |
307,692 | $9.75 | $2,999,997 | 3,482,224 (Indirect) |
View |
| 2019-06-24 Purchase |
2019-06-26 4:51 pm |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
200,000 | $9 | $1,800,000 | 4,900,249 (Indirect) |
View |
| 2018-07-13 Purchase |
2018-10-22 2:54 pm |
ARQULE INC | ARQL | Nussbaum Ran Director |
181,818 | $5.5 | $999,999 | 3,348,676 (Indirect) |
View |
| 2018-05-18 Purchase(A) |
2018-05-22 09:22 am |
ARQULE INC | ARQL | Nussbaum Ran Director |
8,611 | $3.29 | $28,330 | 3,259,000 (Indirect) |
View |
| 2018-05-18 Purchase |
2018-05-18 5:41 pm |
ARQULE INC | ARQL | Nussbaum Ran Director |
8,611 | $3.29 | $28,330 | 8,611 (Direct) |
View |
| 2018-04-30 Purchase |
2018-05-01 4:34 pm |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
350,000 | $9.75 | $3,412,500 | 4,900,249 (Indirect) |
View |
| 2018-03-21 Purchase |
2018-03-23 4:20 pm |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
12,600 | $7.764 | $97,830 | 4,900,249 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2019-06-03 Option Award |
2019-06-05 4:55 pm |
N/A 2029-06-02 |
UroGen Pharma Ltd. | URGN | Nussbaum Ran Director |
10,000 | $34.83 | 10,000 (Direct) |
View |
| 2019-05-29 Option Award |
2019-05-30 3:45 pm |
N/A 2029-05-29 |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
20,000 | $9.02 | 20,000 (Direct) |
View |
| 2019-05-29 Option Award |
2019-05-29 5:21 pm |
N/A 2029-05-29 |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
20,000 | $9.02 | 20,000 (Direct) |
View |
| 2019-05-14 Option Award |
2019-05-15 12:44 pm |
N/A 2029-05-13 |
ARQULE INC | ARQL | Nussbaum Ran Director |
40,000 | $6.21 | 40,000 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-19 6:17 pm |
N/A 2028-06-15 |
Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director |
40,000 | $23.27 | 40,000 (Direct) |
View |
| 2018-05-08 Other |
2018-05-25 4:30 pm |
N/A N/A |
ARQULE INC | ARQL | Nussbaum Ran Director |
1,762,000 | $0 | 3,259,000 (Indirect) |
View |
| 2018-05-08 Other |
2018-05-25 4:30 pm |
N/A N/A |
ARQULE INC | ARQL | Nussbaum Ran Director |
3,259,000 | $0 | 3,259,000 (Indirect) |
View |
| 2018-05-08 Other |
2018-05-25 4:30 pm |
N/A N/A |
ARQULE INC | ARQL | Nussbaum Ran Director |
1,587,000 | $0 | 3,259,000 (Indirect) |
View |
| 2018-05-08 Other |
2018-05-25 4:30 pm |
N/A 2022-05-08 |
ARQULE INC | ARQL | Nussbaum Ran Director |
476,000 | $1.75 | 3,259,000 (Indirect) |
View |
| 2018-05-08 Other |
2018-05-25 4:30 pm |
N/A 2022-05-08 |
ARQULE INC | ARQL | Nussbaum Ran Director |
880,000 | $1.75 | 3,259,000 (Indirect) |
View |
| 2018-05-08 Other |
2018-05-25 4:30 pm |
N/A 2022-05-08 |
ARQULE INC | ARQL | Nussbaum Ran Director |
428,000 | $1.75 | 3,259,000 (Indirect) |
View |
| 2018-05-08 Option Award |
2018-05-10 12:45 pm |
N/A 2028-05-08 |
ARQULE INC | ARQL | Nussbaum Ran Director |
20,000 | $2.48 | 20,000 (Direct) |
View |
| 2017-11-08 Option Award |
2017-11-09 12:14 pm |
N/A 2027-11-08 |
ARQULE INC | ARQL | Nussbaum Ran Director |
30,000 | $1.1 | 30,000 (Direct) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A N/A |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
4,360 | $0 | 0 (Direct) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A N/A |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
3,520 | $0 | 0 (Indirect) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A N/A |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
2,651 | $0 | 0 (Indirect) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A N/A |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
1,029 | $0 | 0 (Indirect) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A N/A |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
2,632 | $0 | 0 (Indirect) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A 2024-03-24 |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
50,000 | $178.6 | 0 (Direct) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A 2025-06-08 |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
10,000 | $120.8 | 0 (Direct) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A 2026-05-31 |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
7,000 | $129.1 | 0 (Direct) |
View |
| 2017-10-03 Disposition |
2017-10-05 8:26 pm |
N/A 2027-06-19 |
Kite Pharma Inc. | KITE | Nussbaum Ran Director |
8,810 | $88.79 | 0 (Direct) |
View |
|
© 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 2016 2015 2014 ... Fri, 19 Jul 2019 07:22:07 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |